2009 Meeting Materials of the Blood Products Advisory Committee
November 16-17, 2009 Meeting of the Blood Products Advisory Committee
On November 16, 2009, in the morning the Committee will hear updates on the following topics: the HHS Advisory Committee on Blood Safety and Availability, Dengue virus outbreak, and 2009 A/H1N1 Pandemic and the impact on blood safety and availability.
July 20-21, 2009 Meeting of the Blood Products Advisory Committee
On July 20, 2009, in the morning, the Committee will review proposed strategies to demonstrate the effectiveness of new coral snake antivenoms. In the afternoon the Committee will discuss alternative clinical and surrogate endpoints for evaluating efficacy of Alpha-1 Proteinase Inhibitor (Human) augmentation therapy in Alpha-1 antitrypsin deficiency.
- Announcement [ARCHIVED]
- Draft Agenda (PDF - 29KB) [ARCHIVED]
- Final Agenda (PDF - 40KB) [ARCHIVED]
- Meeting Roster (PDF - 64KB) [ARCHIVED]
- Meeting Materials [ARCHIVED]
- Presentations [ARCHIVED]
- References (PDF - 86KB) [ARCHIVED]
- Summary Minutes (PDF - 46KB) [ARCHIVED]
- Transcripts [ARCHIVED]
- Waivers for Conflicts of Interest [ARCHIVED]
April 1-2, 2009 Meeting of the Blood Products Advisory Committee
On April 1, 2009, the Committee will hear updates on the following topics: National Biovigilance Data Collection and Analysis Program; a summary of the December 16-17, 2008, meeting of the Department of Health and Human Services Advisory Committee on Blood Safety and Availability; and a summary of the September 12, 2008, FDA Workshop on Approaches to Minimize the Risk of Transfusion-Transmitted Babesiosis in the United States.
January 9, 2009 Meeting of the Blood Products Advisory Committee
On the morning of January 9, 2009, the Committee will discuss CSL Behring’s Biologics License Application for plasma-derived fibrinogen concentrate for treatment of bleeding in congenital fibrinogen deficiency. In the afternoon, the Committee will hear an update on the “Food and Drug Administration Draft Guidance for Industry on Regulation of Genetically Engineered Animals Containing Heritable Recombinant DNA Constructs.”